Literature DB >> 14649724

T-588 protects motor neuron death against glutamate-induced neurotoxicity.

Yasuo Iwasaki1, Yasumitsu Ichikawa, Osamu Igarasi, Joe Aoyagi, Shingo Konno, Ken Ikeda, Hiroaki Iguchi, Seiichi Kawabe, Shigeki Marubuchi, Satoshi Ono.   

Abstract

To examine the possible neuroprotective effect of T-588 against glutamate-induced neurotoxicity, we analyzed the pharmacological utility of T-588 in a postnatal organotypic culture model of motor neuron degeneration. Treatment with 10(-5) M of glutamate resulted a motor neuron loss and decreased activity of choline acetyltransferase (ChAT). Cotreatment of 10(-5) M of glutamate and T-588 revealed a protective effect against motor neuron death and decreased ChAT activity. We concluded that T-588 may play important roles in the survival and maintenance of spinal motor neurons in its neuroprotection against glutamate-induced neurotoxicity. Our data may provide a rationale for designing a therapeutic strategy for protection against pathologically induced motor neuron damage or cell death such as amyotrophic lateral sclerosis and motor neuropathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14649724     DOI: 10.1023/a:1026167624054

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  14 in total

1.  Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration.

Authors:  M M Bilak; A M Corse; S R Bilak; M Lehar; J Tombran-Tink; R W Kuncl
Journal:  J Neuropathol Exp Neurol       Date:  1999-07       Impact factor: 3.685

Review 2.  Excitotoxicity in ALS.

Authors:  P N Leigh; B S Meldrum
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

3.  T-588 inhibits astrocyte apoptosis via mitogen-activated protein kinase signal pathway.

Authors:  K Takuma; T Fujita; Y Kimura; M Tanabe; A Yamamuro; E Lee; K Mori; Y Koyama; A Baba; T Matsuda
Journal:  Eur J Pharmacol       Date:  2000-06-30       Impact factor: 4.432

4.  Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; M Van Kammen; A I Levey; L J Martin; R W Kuncl
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

Review 5.  Excitatory amino acids as a final common pathway for neurologic disorders.

Authors:  S A Lipton; P A Rosenberg
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

Authors:  L Lacomblez; G Bensimon; P N Leigh; P Guillet; V Meininger
Journal:  Lancet       Date:  1996-05-25       Impact factor: 79.321

Review 7.  Excitotoxicity and motor neurone disease: a review of the evidence.

Authors:  P J Shaw
Journal:  J Neurol Sci       Date:  1994-07       Impact factor: 3.181

8.  A new cognition-enhancing agent, (R)-(-)-1-(benzo[b]thiophen-5-yl)- 2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride. Effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions.

Authors:  S Ono; T Yamafuji; H Chaki; Y Todo; M Maekawa; K Kitamura; T Kimura; Y Nakada; K Mozumi; H Narita
Journal:  Biol Pharm Bull       Date:  1995-12       Impact factor: 2.233

Review 9.  Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis.

Authors:  Yasuo Iwasaki; Ken Ikeda; Masao Kinoshita
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-10

Review 10.  Oxidative stress, glutamate, and neurodegenerative disorders.

Authors:  J T Coyle; P Puttfarcken
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

View more
  1 in total

1.  Time course of changes in immunoreactivities of GABA degradation enzymes in the hippocampal CA1 region after adrenalectomy in gerbils.

Authors:  In Koo Hwang; Ki-Yeon Yoo; Hua Li; Jung Hoon Choi; Choong Hyun Lee; Dae Won Chung; In Se Lee; Dae Won Kim; Soo Young Choi; Moo-Ho Won
Journal:  Neurochem Res       Date:  2007-11-21       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.